CA2914040A1 — Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
Assigned to Bayer Pharma AG · Expires 2014-12-11 · 11y expired
What this patent protects
The invention relates to substituted triazolopyridines and methods for the production thereof, as well as to the use thereof in the production of drugs for treating and/or preventing diseases, especially diseases of the cardiovascular system, preferably thrombotic or thromboembol…
USPTO Abstract
The invention relates to substituted triazolopyridines and methods for the production thereof, as well as to the use thereof in the production of drugs for treating and/or preventing diseases, especially diseases of the cardiovascular system, preferably thrombotic or thromboembolic diseases.
Drugs covered by this patent
- Adempas (RIOCIGUAT) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.